ROL' tsITOKINOV V RAZVITII SERDEChNO-SOSUDISTyKh ZABOLEVANIY I OSTEOPOROZA

Ершова, О. Б.; Belova, K. Yu.; Новикова, Я. В.; Баранов, А. А.; Назарова, А. В.; Romanova, M.

doi:10.14341/osteo2011333-35

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained during the study of the atherosclerotic areas of carotid arteries in humans (Shishkina et al, 2014). Besides, the experiments on the modeled AS in animals with inhibited pro-inflammatory cytokines indicated the slowdown of the process of the development and progression of the disease (Tedgui and Mallat, 2001;Ershova et al, 2011;Miossec, 2009). Thus, one of the targets for antiatherosclerotic drugs (АAD) can be proinflammatory cytokines.…”

Section: Drugs That Affect the Synthesis And Effects Of Cytokinesmentioning

confidence: 99%

Modern Opportunities of Atherosclerosis Pharmacotherapy: New Directions

Дутова¹,

Saranchina²,

Килина³

et al. 2020

PTQ

View full text Add to dashboard Cite

Despite the successful achievements in modern applied medicine and the application of hypolipidemic drugs into clinical practice for the past 50 years, the issue of prevention and treatment of atherosclerotic vascular disease (AVD) remains unsolved. Implementation of the theory of immunopathogenesis of atherosclerosis that was experimentally proved by modern studies allows the specialists to expand the possibilities of pharmacotherapy and pharmacoprevention for AVD. Thus, the aim of the present study was to analyze new directions in the development of anti-atherosclerotic drugs (AAD) with a pathogenetic activity that suppressed chronic autoimmune inflammation in the areas of atherosclerotic damage of vessels. In the course of the study, the search and analysis of the publications in the databases Web of Science, PubMed, and RSCI (Russian Science Citation Index) for the period of 2016-2018 were performed. According to the performed analysis, the most perspective molecular targets for AAD are pro-inflammatory and anti-inflammatory cytokines that develop a disbalance in patients with AVD. Thus, the drugs that are based on monoclonal antibodies to the tumor necrosis factor α (TNFα), and pro-inflammatory interleukins (1β, 17А), used for the treatment of rheumatoid arthritis and psoriasis, can be used for the treatment of AVD. Recombinant interleukins 6, 13, 19, and substances that suppress the expression of interferon regulatory factors will also exert an antiatherogenic effect. The studies on the modeling of the pathogenesis of AVD in inbred animals showed that other molecular targets for AAD could be enzymes involved in the lipid and immune cells metabolism. They include inositol requiring enzyme 1, proprotein convertase subtilisin/Kexin type 9, and the enzymes of paraoxonase family. Besides, the review includes the discussion of the successful application of drugs based on monoclonal antibodies to TNFα (infliximab), IL-17A (secukinumab) and IL-1β (canakinumab), as well as the drugs with antienzymatic activity (evolocumab and darapladib), in clinical practice for the treatment of AVD. The modern knowledge on molecular mechanisms of immunopathogenesis can give grounds for the development of drugs for pathogenetic pharmacotherapy and pharmacoprevention for the complications of AVD. The most effective solution would be the indication of drugs that affect the disbalance of cytokines and metabolic processes in the immune cells.

show abstract

Section: Drugs That Affect the Synthesis And Effects Of Cytokinesmentioning

confidence: 99%

Modern Opportunities of Atherosclerosis Pharmacotherapy: New Directions

Дутова¹,

Saranchina²,

Килина³

et al. 2020

PTQ

View full text Add to dashboard Cite

show abstract

Heart failure and osteoporosis: common pathogenetic components

Скрипникова¹,

Yaralieva²,

Драпкина³

2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

This literature review reflects modern ideas about the combination of heart failure (HF) and osteoporosis, common risk factors for these diseases, and pathophysiological mechanisms of metabolic bone diseases in HF. Despite a growing number of studies on the combined cardiovascular and skeletal system pathology, the relationship between a decrease in bone mineral density and HF risk remains poorly understood. Both conditions are common causes of disability, death, prolonged hospitalizations and a significant reduction in quality of life, while its combination exacerbates their course and increases the incidence of adverse outcomes, which is a heavy burden for a patient and health care in general. Keywords: heart failure, osteoporosis, bone mineral density, bone metabolism.

show abstract

Cytokines and atherosclerosis – new research directions

et al. 2018

View full text Add to dashboard Cite

This review generalizes the current evidence on the content of the pro- and anti-inflammatory cytokines in patients’ blood serum with atherosclerotic lesions of the coronary, carotid and iliac arteries. The results gave the ability to assess cytokine immune cells of atherosclerotic plaques. Also the results of national and international research allowed the assessment of the prognostic value of cytokine content.

show abstract

ROL' tsITOKINOV V RAZVITII SERDEChNO-SOSUDISTyKh ZABOLEVANIY I OSTEOPOROZA

Cited by 3 publications

References 34 publications

Modern Opportunities of Atherosclerosis Pharmacotherapy: New Directions

Modern Opportunities of Atherosclerosis Pharmacotherapy: New Directions

Heart failure and osteoporosis: common pathogenetic components

Cytokines and atherosclerosis – new research directions

Contact Info

Product

Resources

About